Mr. Steven Pincus, Ph.D., a Consultant/SME at Shabas Solutions LLC, has over thirty-five years of experience in multiple roles in the Pharmaceutical and Biotechnology industries in research and development of vaccines and gene therapy products with 30+ publications and 10+ patents. He currently supports NIH National Institute of Neurological Disorders and Stroke (NINDS) Blueprint Therapeutic Network (BPN) program focused on neurotherapeutics discovery and development.
Dr. Pincus retired after most recently serving as Executive Director Analytical Development at Neurogene, where he led a team that developed the analytical assays including potency assays to allow submission of INDs for several gene therapy candidates to treat neurological diseases in children. Prior to that he was the Associate VP of Virology and Analytical Development and Head of Science and Innovation at Fujifilm Diosynth Biotechnologies site in Texas where he led teams that assisted clients in analytical development for vaccines and gene therapy projects and supported process Development and Quality Control. His team also worked on the development of a manufacturing process and supporting analytics to allow Fuji to offer a single platform for use by clients for manufacturing AAV gene therapy projects based on multiple serotypes.
Dr. Pincus was Director Clinical and Regulatory Affairs and Senior Director Virology and Animal Biology at Elusys Therapeutics where he helped develop an antibody that was licensed for treatment and prevention of anthrax disease. At Novavax Dr Pincus supported the development of Influenza seasonal vaccines and the analytical assays and reagents necessary to release them for clinical trials. At Virogenetics, Dr Pincus was Research Scientist, Platform Leader Molecular Biology/Microbiology, Senior Scientist and discovered a way to create Poxvirus vectors that expressed a subviral particle as a vaccine for several Flaviviruses. His discovery led to a West Nile Vaccine for Horses. He also identified Human Cytomegalovirus proteins involved in eliciting cytolytic T cells and helped develop vaccine candidates.
Dr. Pincus received his Bachelor of Science and Ph.D in Biochemistry from the State University at Buffalo. He performed postdoctoral research Under an NIH Postdoctoral Fellowship at State University at Stoney Brook.